Listed

Senti Biosciences Holdings, Inc.

SNTINasdaqCIK 1854270HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$17.0k, Q2 FY2026
Operating income−$14.5m, Q2 FY2026
Net income−$12.8m, Q2 FY2026
Senti Biosciences Holdings, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.3Revenue, Q3 FY2023, three months to 2023-09-30$255.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figure0.0Revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-20, accession 0001854270-25-000042. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-05-09, accession 0001854270-24-000052.Report this figure0.0Revenue, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-08-13, accession 0001854270-24-000101.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figurenot reportednot reported0.0Revenue, Q1 FY2026, three months to 2026-03-31$16.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$17.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure
Research and development$m9.1Research and development, Q3 FY2023, three months to 2023-09-30$9.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figure9.1Research and development, Q4 FY2023, three months to 2023-12-31$9.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-20, accession 0001854270-25-000042. Derived: 12-month figure less the 9-month figure.Report this figure8.8Research and development, Q1 FY2024, three months to 2024-03-31$8.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-06, accession 0001854270-25-000065.Report this figure9.2Research and development, Q2 FY2024, three months to 2024-06-30$9.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0001854270-25-000090.Report this figure8.7Research and development, Q3 FY2024, three months to 2024-09-30$8.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure7.8Research and development, Q4 FY2024, three months to 2024-12-31$7.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figure9.3Research and development, Q1 FY2025, three months to 2025-03-31$9.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure10.0Research and development, Q2 FY2025, three months to 2025-06-30$10.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure10.5Research and development, Q3 FY2025, three months to 2025-09-30$10.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure7.8Research and development, Q4 FY2025, three months to 2025-12-31$7.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figure5.3Research and development, Q1 FY2026, three months to 2026-03-31$5.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure7.8Research and development, Q2 FY2026, three months to 2026-06-30$7.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure
Operating income$m(43.9)Operating income, Q3 FY2023, three months to 2023-09-30−$43.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figure(18.7)Operating income, Q4 FY2023, three months to 2023-12-31−$18.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-20, accession 0001854270-25-000042. Derived: 12-month figure less the 9-month figure.Report this figure(16.3)Operating income, Q1 FY2024, three months to 2024-03-31−$16.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-06, accession 0001854270-25-000065.Report this figure(13.4)Operating income, Q2 FY2024, three months to 2024-06-30−$13.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0001854270-25-000090.Report this figure(15.2)Operating income, Q3 FY2024, three months to 2024-09-30−$15.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure(16.2)Operating income, Q4 FY2024, three months to 2024-12-31−$16.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figure(16.4)Operating income, Q1 FY2025, three months to 2025-03-31−$16.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure(16.8)Operating income, Q2 FY2025, three months to 2025-06-30−$16.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure(16.9)Operating income, Q3 FY2025, three months to 2025-09-30−$16.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure(18.6)Operating income, Q4 FY2025, three months to 2025-12-31−$18.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figure(4.6)Operating income, Q1 FY2026, three months to 2026-03-31−$4.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure(14.5)Operating income, Q2 FY2026, three months to 2026-06-30−$14.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figurenot reported0.0Income tax, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-06, accession 0001854270-25-000065.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-07, accession 0001854270-25-000090.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure
Net income$m(14.9)Net income, Q3 FY2023, three months to 2023-09-30−$14.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figure(71.1)Net income, Q4 FY2023, three months to 2023-12-31−$71.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-21, accession 0001854270-24-000029.Report this figure(12.1)Net income, Q1 FY2024, three months to 2024-03-31−$12.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure(11.2)Net income, Q2 FY2024, three months to 2024-06-30−$11.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure(28.9)Net income, Q3 FY2024, three months to 2024-09-30−$28.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure(0.6)Net income, Q4 FY2024, three months to 2024-12-31−$610.0k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figure(14.1)Net income, Q1 FY2025, three months to 2025-03-31−$14.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure(14.7)Net income, Q2 FY2025, three months to 2025-06-30−$14.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure(18.1)Net income, Q3 FY2025, three months to 2025-09-30−$18.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure(14.5)Net income, Q4 FY2025, three months to 2025-12-31−$14.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figure(4.2)Net income, Q1 FY2026, three months to 2026-03-31−$4.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure(12.8)Net income, Q2 FY2026, three months to 2026-06-30−$12.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure
Diluted EPS$ per share(3.36)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$3.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figurenot reported(2.65)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$2.65 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-06, accession 0001854270-25-000065.Report this figure(2.45)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$2.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001854270-25-000090.Report this figure(6.31)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$6.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figurenot reported(1.41)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure(0.56)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.56 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure(0.69)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figurenot reported(0.14)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure(0.41)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure
Basic EPS$ per share(3.36)Basic EPS, Q3 FY2023, three months to 2023-09-30−$3.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figurenot reported(2.65)Basic EPS, Q1 FY2024, three months to 2024-03-31−$2.65 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-06, accession 0001854270-25-000065.Report this figure(2.45)Basic EPS, Q2 FY2024, three months to 2024-06-30−$2.45 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0001854270-25-000090.Report this figure(6.31)Basic EPS, Q3 FY2024, three months to 2024-09-30−$6.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figurenot reported(1.41)Basic EPS, Q1 FY2025, three months to 2025-03-31−$1.41 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure(0.56)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.56 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure(0.69)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.69 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figurenot reported(0.14)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure(0.41)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.41 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure

Balance sheet

Cash and equivalents$6.5m, Q2 FY2026
Shareholders' equity−$3.4m, Q2 FY2026
Senti Biosciences Holdings, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m39.4Cash and equivalents, Q3 FY2023, at 2023-09-30$39.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figure35.9Cash and equivalents, FY2023, at 2023-12-31$35.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-20, accession 0001854270-25-000042.Report this figure23.7Cash and equivalents, Q1 FY2024, at 2024-03-31$23.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0001854270-24-000052.Report this figure15.9Cash and equivalents, Q2 FY2024, at 2024-06-30$15.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-13, accession 0001854270-24-000101.Report this figure10.5Cash and equivalents, Q3 FY2024, at 2024-09-30$10.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figure48.3Cash and equivalents, FY2024, at 2024-12-31$48.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-27, accession 0001628280-26-021580.Report this figure33.8Cash and equivalents, Q1 FY2025, at 2025-03-31$33.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-06, accession 0001854270-25-000065.Report this figure21.6Cash and equivalents, Q2 FY2025, at 2025-06-30$21.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0001854270-25-000090.Report this figure12.2Cash and equivalents, Q3 FY2025, at 2025-09-30$12.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure16.4Cash and equivalents, FY2025, at 2025-12-31$16.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure8.9Cash and equivalents, Q1 FY2026, at 2026-03-31$8.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure6.5Cash and equivalents, Q2 FY2026, at 2026-06-30$6.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure
Current assets$m79.0Current assets, Q3 FY2023, at 2023-09-30$79.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-14, accession 0001854270-23-000129.Report this figure71.2Current assets, FY2023, at 2023-12-31$71.2m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-20, accession 0001854270-25-000042.Report this figure55.7Current assets, Q1 FY2024, at 2024-03-31$55.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0001854270-24-000052.Report this figure44.3Current assets, Q2 FY2024, at 2024-06-30$44.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-13, accession 0001854270-24-000101.Report this figure17.4Current assets, Q3 FY2024, at 2024-09-30$17.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figure59.0Current assets, FY2024, at 2024-12-31$59.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-27, accession 0001628280-26-021580.Report this figure45.2Current assets, Q1 FY2025, at 2025-03-31$45.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-06, accession 0001854270-25-000065.Report this figure32.5Current assets, Q2 FY2025, at 2025-06-30$32.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0001854270-25-000090.Report this figure18.2Current assets, Q3 FY2025, at 2025-09-30$18.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure23.3Current assets, FY2025, at 2025-12-31$23.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure14.8Current assets, Q1 FY2026, at 2026-03-31$14.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure13.0Current assets, Q2 FY2026, at 2026-06-30$13.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure
Total assets$m132Total assets, Q3 FY2023, at 2023-09-30$131.8m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0001854270-23-000129.Report this figure119Total assets, FY2023, at 2023-12-31$119.5m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-20, accession 0001854270-25-000042.Report this figure102Total assets, Q1 FY2024, at 2024-03-31$102.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0001854270-24-000052.Report this figure86.9Total assets, Q2 FY2024, at 2024-06-30$86.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-13, accession 0001854270-24-000101.Report this figure57.7Total assets, Q3 FY2024, at 2024-09-30$57.7m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figure97.8Total assets, FY2024, at 2024-12-31$97.8m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-27, accession 0001628280-26-021580.Report this figure82.8Total assets, Q1 FY2025, at 2025-03-31$82.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-06, accession 0001854270-25-000065.Report this figure68.5Total assets, Q2 FY2025, at 2025-06-30$68.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0001854270-25-000090.Report this figure52.7Total assets, Q3 FY2025, at 2025-09-30$52.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure51.2Total assets, FY2025, at 2025-12-31$51.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure38.2Total assets, Q1 FY2026, at 2026-03-31$38.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure33.1Total assets, Q2 FY2026, at 2026-06-30$33.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure
Current liabilities$m10.1Current liabilities, Q3 FY2023, at 2023-09-30$10.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-14, accession 0001854270-23-000129.Report this figure12.7Current liabilities, FY2023, at 2023-12-31$12.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-20, accession 0001854270-25-000042.Report this figure9.6Current liabilities, Q1 FY2024, at 2024-03-31$9.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0001854270-24-000052.Report this figure9.1Current liabilities, Q2 FY2024, at 2024-06-30$9.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-13, accession 0001854270-24-000101.Report this figure9.1Current liabilities, Q3 FY2024, at 2024-09-30$9.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figure13.1Current liabilities, FY2024, at 2024-12-31$13.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-27, accession 0001628280-26-021580.Report this figure10.7Current liabilities, Q1 FY2025, at 2025-03-31$10.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-06, accession 0001854270-25-000065.Report this figure10.0Current liabilities, Q2 FY2025, at 2025-06-30$10.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0001854270-25-000090.Report this figure12.0Current liabilities, Q3 FY2025, at 2025-09-30$12.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure14.0Current liabilities, FY2025, at 2025-12-31$14.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure14.3Current liabilities, Q1 FY2026, at 2026-03-31$14.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure15.8Current liabilities, Q2 FY2026, at 2026-06-30$15.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure
Total liabilities$m48.8Total liabilities, Q3 FY2023, at 2023-09-30$48.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-14, accession 0001854270-23-000129.Report this figure52.6Total liabilities, FY2023, at 2023-12-31$52.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-20, accession 0001854270-25-000042.Report this figure46.1Total liabilities, Q1 FY2024, at 2024-03-31$46.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0001854270-24-000052.Report this figure42.8Total liabilities, Q2 FY2024, at 2024-06-30$42.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-13, accession 0001854270-24-000101.Report this figure41.7Total liabilities, Q3 FY2024, at 2024-09-30$41.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figure47.1Total liabilities, FY2024, at 2024-12-31$47.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-27, accession 0001628280-26-021580.Report this figure44.9Total liabilities, Q1 FY2025, at 2025-03-31$44.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-06, accession 0001854270-25-000065.Report this figure43.9Total liabilities, Q2 FY2025, at 2025-06-30$43.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0001854270-25-000090.Report this figure44.6Total liabilities, Q3 FY2025, at 2025-09-30$44.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure45.6Total liabilities, FY2025, at 2025-12-31$45.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure35.7Total liabilities, Q1 FY2026, at 2026-03-31$35.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure36.5Total liabilities, Q2 FY2026, at 2026-06-30$36.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure
Shareholders' equity$m82.9Shareholders' equity, Q3 FY2023, at 2023-09-30$82.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figure66.9Shareholders' equity, FY2023, at 2023-12-31$66.9m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-27, accession 0001628280-26-021580.Report this figure56.1Shareholders' equity, Q1 FY2024, at 2024-03-31$56.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure44.1Shareholders' equity, Q2 FY2024, at 2024-06-30$44.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure16.0Shareholders' equity, Q3 FY2024, at 2024-09-30$16.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure25.6Shareholders' equity, FY2024, at 2024-12-31$25.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure37.9Shareholders' equity, Q1 FY2025, at 2025-03-31$37.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure24.7Shareholders' equity, Q2 FY2025, at 2025-06-30$24.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure8.1Shareholders' equity, Q3 FY2025, at 2025-09-30$8.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure5.6Shareholders' equity, FY2025, at 2025-12-31$5.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure2.6Shareholders' equity, Q1 FY2026, at 2026-03-31$2.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure(3.4)Shareholders' equity, Q2 FY2026, at 2026-06-30−$3.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure

Cash flow

Operating cash flow−$14.2m, Q2 FY2026
Capital expenditure$0, Q4 FY2025
Senti Biosciences Holdings, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(15.4)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$15.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-14, accession 0001854270-24-000116. Derived: 9-month figure less the 6-month figure.Report this figure(7.0)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$7.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-20, accession 0001854270-25-000042. Derived: 12-month figure less the 9-month figure.Report this figure(11.7)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$11.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-06, accession 0001854270-25-000065.Report this figure(8.3)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$8.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001854270-25-000090. Derived: 6-month figure less the 3-month figure.Report this figure(7.9)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$7.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001628280-25-052125. Derived: 9-month figure less the 6-month figure.Report this figure(13.5)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$13.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figure(14.1)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$14.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure(13.1)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$13.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001628280-26-057110. Derived: 6-month figure less the 3-month figure.Report this figure(9.4)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$9.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001628280-25-052125. Derived: 9-month figure less the 6-month figure.Report this figure(6.9)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$6.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figure(7.5)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$7.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure(14.2)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$14.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001628280-26-057110. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m1.9Capital expenditure, Q3 FY2023, three months to 2023-09-30$1.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-14, accession 0001854270-24-000116. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$4.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-20, accession 0001854270-25-000042. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$15.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-06, accession 0001854270-25-000065.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-07, accession 0001854270-25-000090. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001628280-25-052125. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$11.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-06, accession 0001854270-25-000065.Report this figure0.2Capital expenditure, Q2 FY2025, three months to 2025-06-30$196.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001628280-26-057110. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001628280-25-052125. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-27, accession 0001628280-26-021580. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)31.14m, Q2 FY2026
Senti Biosciences Holdings, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares43.4Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3043,424,172 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0001854270-23-000129.Report this figure44.1Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3144,070,974 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0001854270-24-000052.Report this figure4.4Diluted shares (weighted), Q2 FY2023, three months to 2023-06-304,427,726 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-13, accession 0001854270-24-000101.Report this figure4.4Diluted shares (weighted), Q3 FY2023, three months to 2023-09-304,447,223 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-14, accession 0001854270-24-000116.Report this figure4.6Diluted shares (weighted), Q1 FY2024, three months to 2024-03-314,570,744 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-06, accession 0001854270-25-000065.Report this figure4.6Diluted shares (weighted), Q2 FY2024, three months to 2024-06-304,572,010 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0001854270-25-000090.Report this figure4.6Diluted shares (weighted), Q3 FY2024, three months to 2024-09-304,577,122 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure10.0Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3110,012,908 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure26.1Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3026,081,273 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure26.2Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3026,228,274 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-13, accession 0001628280-25-052125.Report this figure31.0Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3130,971,573 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-14, accession 0001628280-26-035126.Report this figure31.1Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3031,144,754 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure

Shares outstanding: 31.14mShares outstanding, period not labelled, at 2026-07-3131,144,754 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001628280-26-057110.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.